Treatment of HER2 Positive Breast Cancer with Paclitaxel and Trastuzumab

Yi Shen

doi:10.54254/2753-8818/2025.AU28743

Theoretical and Natural ScienceOpen access

Treatment of HER2 Positive Breast Cancer with Paclitaxel and Trastuzumab

Research Article

Open Access

Treatment of HER2 Positive Breast Cancer with Paclitaxel and Trastuzumab

Yi Shen ^1*

¹ China Pharmaceutical University

^*Corresponding author: sy61@stu.cpu.edu.cn

Published on 28 October 2025

TNS Vol.147

ISSN (Print): 2753-8826

ISSN (Online): 2753-8818

ISBN (Print): 978-1-80590-489-2

ISBN (Online): 978-1-80590-490-8

Download Cover

Abstract

Breast cancer is one of the most common cancers among Chinese women, involving various mechanisms such as gene mutations, hormone stimulation, and abnormal signaling pathways. This paper focuses on HER2 positive breast cancer and discusses the use of the chemotherapy drug paclitaxel and the monoclonal antibody trastuzumab. Paclitaxel is a broad-spectrum anti-cancer drug that primarily acts by targeting microtubules and has a unique nano-delivery system. Trastuzumab is one of the preferred drugs for treating HER2 positive breast cancer and specifically binds to HER2 to inhibit tumor cell growth. The combination of paclitaxel and trastuzumab can enhance the efficacy against HER2-positive breast cancer to a certain extent, but further research is needed. Additionally, the resistance to paclitaxel and the cardiotoxicity of trastuzumab are discussed in the paper.

Keywords:

Breast cancer, HER2 positive, Paclitaxel, Trastuzumab, Antibody-drug conjugate

View PDF

References

[1]. F. Zhao, Y. Cai, X. Guo, C. Xu, and B. Ma, “Impact and trend analysis of low physical activity on the disease burden of breast cancer among Chinese women, ” Clinical Education of General Practice, vol. 23, no. 07, pp. 623-628+673, Jul. 2025, doi: 10.13558/j.cnki.issn1672-3686.2025.007.012.

[2]. L. Wilkinson and T. Gathani, “Understanding Breast Cancer as a Global Health Concern, ” The British Journal of Radiology, vol. 95, no. 1130, Dec. 2021, doi: https: //doi.org/10.1259/bjr.20211033.

[3]. C. Katsura, I. Ogunmwonyi, H. K. Kankam, and S. Saha, “Breast Cancer: Presentation, Investigation and Management, ” British Journal of Hospital Medicine, vol. 83, no. 2, pp. 1–7, Feb. 2022, doi: https: //doi.org/10.12968/hmed.2021.0459.

[4]. B. Han et al., “Cancer incidence and mortality in China, 2022, ” Journal of the National Cancer Center, vol. 4, no. 1, pp. 47–53, Feb. 2024, doi: https: //doi.org/10.1016/j.jncc.2024.01.006.

[5]. X. Xiong et al., “Breast cancer: pathogenesis and treatments, ” Signal Transduction and Targeted Therapy, vol. 10, no. 1, Feb. 2025, doi: https: //doi.org/10.1038/s41392-024-02108-4.

[6]. Z. S. Lima, M. Ghadamzadeh, F. T. Arashloo, G. Amjad, M. R. Ebadi, and L. Younesi, “Recent advances of therapeutic targets based on the molecular signature in breast cancer: genetic mutations and implications for current treatment paradigms, ” Journal of Hematology & Oncology, vol. 12, no. 1, Apr. 2019, doi: https: //doi.org/10.1186/s13045-019-0725-6.

[7]. Kanwal Raghav and M. M. Moasser, “Molecular Pathways and Mechanisms of HER2 in Cancer Therapy, ” Clinical Cancer Research, vol. 29, no. 13, pp. 2351–2361, Dec. 2022, doi: https: //doi.org/10.1158/1078-0432.ccr-22-0283.

[8]. M. Park, D. Kim, S. Ko, A. Kim, K. Mo, and H. Yoon, “Breast Cancer Metastasis: Mechanisms and Therapeutic Implications, ” International Journal of Molecular Sciences, vol. 23, no. 12, p. 6806, Jun. 2022, doi: https: //doi.org/10.3390/ijms23126806.

[9]. Y. Choi et al., “Novel insights into paclitaxel’s role on tumor-associated macrophages in enhancing PD-1 blockade in breast cancer treatment, ” Journal for ImmunoTherapy of Cancer, vol. 12, no. 7, p. e008864, Jul. 2024, doi: https: //doi.org/10.1136/jitc-2024-008864.

[10]. H. Yu et al., “Paclitaxel anti-cancer therapeutics: from discovery to clinical use, ” Chinese Journal of Natural Medicines, vol. 23, no. 7, pp. 769–789, Jul. 2025, doi: https: //doi.org/10.1016/s1875-5364(25)60833-8.

[11]. J. Sharifi-Rad et al., “Paclitaxel: Application in Modern Oncology and Nanomedicine-Based Cancer Therapy, ” Oxidative Medicine and Cellular Longevity, vol. 2021, p. 3687700, Oct. 2021, doi: https: //doi.org/10.1155/2021/3687700.

[12]. S. M. Swain, M. Shastry, and E. Hamilton, “Targeting HER2-positive breast cancer: advances and future directions, ” Nature Reviews Drug Discovery, vol. 22, no. 2, pp. 101–126, Nov. 2022.

[13]. S. A. Hurvitz et al., “Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial, ” The Lancet, vol. 401, no. 10371, pp. 105–117, Dec. 2022, doi: https: //doi.org/10.1016/S0140-6736(22)02420-5.

[14]. T. P. DiPeri et al., “Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers, ” Clinical Cancer Research, vol. 29, no. 21, pp. 4385–4398, Jun. 2023, doi: https: //doi.org/10.1158/1078-0432.ccr-23-0103.

[15]. Claudia von Arx et al., “The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer, ” Cancer Treatment Reviews, vol. 113, p. 102500, Feb. 2023, doi: https: //doi.org/10.1016/j.ctrv.2022.102500.

[16]. L. Zhang, “Observation on the Efficacy of Neoadjuvant Chemotherapy with Trastuzumab Combined with Paclitaxel in the Treatment of Advanced Breast Cancer, ” Practical Clinical Journal of Integrated Traditional Chinese and Western Medicine, vol. 25, no. 04, pp. 19-22, Feb. 2025, doi: 10.13638/j.issn.1671-4040.2025.04.006.

[17]. S. M. Tolaney et al., “Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial, ” The Lancet Oncology, vol. 24, no. 3, pp. 273–285, Mar. 2023, doi: https: //doi.org/10.1016/s1470-2045(23)00051-7.

[18]. C. Ren et al., “Ubiquitination of NF-κB p65 by FBXW2 suppresses breast cancer stemness, tumorigenesis, and paclitaxel resistance, ” Cell Death & Differentiation, vol. 29, no. 2, pp. 381–392, Aug. 2021, doi: https: //doi.org/10.1038/s41418-021-00862-4.

References

[5]. X. Xiong et al., “Breast cancer: pathogenesis and treatments, ” Signal Transduction and Targeted Therapy, vol. 10, no. 1, Feb. 2025, doi: https: //doi.org/10.1038/s41392-024-02108-4.

[12]. S. M. Swain, M. Shastry, and E. Hamilton, “Targeting HER2-positive breast cancer: advances and future directions, ” Nature Reviews Drug Discovery, vol. 22, no. 2, pp. 101–126, Nov. 2022.

Cite this article

Shen,Y. (2025). Treatment of HER2 Positive Breast Cancer with Paclitaxel and Trastuzumab. Theoretical and Natural Science,147,17-26.

Data availability

The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.

About volume

Volume title: Proceedings of ICBioMed 2025 Symposium: AI for Healthcare: Advanced Medical Data Analytics and Smart Rehabilitation

ISBN: 978-1-80590-489-2(Print) / 978-1-80590-490-8(Online)

Editor: Alan Wang

Conference website: https://2025.icbiomed.org/auckland.html

Conference date: 17 October 2025

Series: Theoretical and Natural Science

Volume number: Vol.147

ISSN: 2753-8818(Print) / 2753-8826(Online)

© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license. Authors who publish this series agree to the following terms:

1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.

2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.

3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open access policy for details).